Kun for helsepersonell

Søk 

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss
OmAlopecia AreataLITFULO virkningsmekanismeSALT EvalueringEffektALLEGRO-2b/3 studieoversiktHårrespons i hodebunnenPasientrapporterte utfallØyenbryn og vipperesponsFør og etter bilderSikkerhetALLEGRO-2b/3 bivirkningerSamlede sikkerhetsdataYtterligere sikkerhetsinformasjonKom i gangDoseringScreening og oppfølgingSette pasientmålPasientprofilerOpplæringsmateriellMateriellVideo
Dosering LITFULO 50 mg. One dose strength. One pill. Once a day.
Scroll left to view table
How to take
  • With or without food
  • Capsules should be swallowed whole; not crushed, split, or chewed
If a dose is missed
  • Patients should take it as soon as possible
  • If less than 8 hours before the next dose, resume dosing at the regular scheduled time
Treatment interruption or discontinuation
  • Interrupt LITFULO if a serious or opportunistic infection develops, and resume treatment once the infection is controlled
  • Interruption or discontinuation of treatment may be needed to manage haematologic abnormalities
 
  • The risk of significant loss of regrown scalp hair after a temporary treatment interruption for less than 6 weeks is low
Update immunisations according to current local guidelines before initiating LITFULO, including prophylactic herpes zoster vaccinations. 
Avoid using live attenuated vaccines during or shortly prior to treatment with LITFULO.Drug Interactions
Scroll left to view table
  Clinical Impact Intervention
Effects of LITFULO on other drugs
CYP3A and CYP1A2 LITFULO is a CYP3A and CYP1A2 inhibitor that may increase the risk of adverse reactions of these substrates Caution should be exercised with concomitant use of LITFULO with other CYP3A and CYPIA2 substrates where moderate concentration changes may lead to serious adverse reactions. Dose adjustment recommendations for the other drugs should be considered
OCT1 substrates The coadministration of a single 400 mg dose of ritlecitinib increased the AUCinf of sumatriptan (an organic cation transporter [OCT]1 substrate) by approximately 1.3- to 1.5-fold relative to the sumatriptan dose given alone. The increase in sumatriptan exposure is not considered clinically relevant Caution should be exercised with concomitant use of ritlecitinib with OCT1 substrates where small concentration changes may lead to serious adverse reactions
Effects of other drugs on LITFULO
Moderate-to-strong inducers or inhibitors of CYP3A Concomitant use of strong CYP3A inducers or inhibitors may affect the AUC of LITFULO The effects of these other drugs on LITFULO were not considered clinically significant, and no dose adjustment is required
Learn how to get patients started on LITFULO Screening og oppfølging LoadingAUC=area under curve; CYP1A2=Cytochrome P450 Family 1 Subfamily A Member 2; CYP3A=Cytochrome P450 Family 3 Subfamily A.ReferencesReference:LITFULO (ritlecitinib) Summary of Product Characteristics.
PP-LGF-NOR-0019 | Utarbeidet 08.2024
Kom i gang Explore safety data SikkerhetLoading

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei